NexImmune Company Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States.
It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.
It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors.
NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Craig Jalbert |
Contact Details
Address: 9119 Gaither Road Gaithersburg, Delaware 20877 United States | |
| Phone | 301 825 9810 |
| Website | neximmune.com |
Stock Details
| Ticker Symbol | NEXI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US65344D2080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Trainer M.B.A. | Consultant |
| Craig R. Jalbert CIRA | President, Treasurer, CS, Principal Executive Officer, Financial Off, and Principal Accounting Off |
| Karen Haslbeck | Head of Human Resources |
| Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering and Protein Design |
| Dr. Robert Douglas Knight M.D. | Chief Medical Officer |
| Chad Rubin | Senior Vice President of Corporate Affairs |
| Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science |
| Matthew Schiller | Head of Business Development |